NMAD NOMAD POWER SOLUTIONS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1335105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-474.2%
TTM EPS YoY-283.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-39.2%
ROA-31.9%
ROIC (approx.)-35.2%
Asset turnover—
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.00x
Current ratio0.78x
Interest coverage-191.93x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio-17.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $254,919 | $726,232 | $898,100 | $1.35M | $1.74M |
| SG&A expense | $4.85M | $2.85M | $4.19M | $2.55M | $3.02M |
| Operating income | -$5.11M | -$3.57M | -$5.09M | -$6.31M | -$6.72M |
| Interest expense | $9,158 | $16,821 | $16,233 | $8,875 | $7,414 |
| Income tax | $1,600 | — | — | — | — |
| Net income | -$6.08M | -$3.59M | -$5.09M | -$6.31M | -$6.73M |
| EPS (basic) | — | -1.59 | -2.66 | -3.99 | -0.50 |
| EPS (diluted) | -1.26 | -1.59 | -2.66 | -3.99 | -0.50 |
| Weighted avg. shares (diluted) | 4.84M | 2.25M | 1.92M | 1.58M | 13.47M |
| Balance sheet | |||||
| Cash & equivalents | $156,000 | $1.04M | $4.20M | $5.35M | $4.82M |
| Receivables | $529,000 | — | — | — | — |
| Inventory | $6.67M | — | — | — | — |
| Current assets | $8.39M | $1.15M | $4.31M | $5.56M | $5.09M |
| PP&E, net | $474,000 | — | — | — | — |
| Intangibles | $147,000 | — | — | — | — |
| Total assets | $11.91M | $1.15M | $4.31M | $5.56M | $5.09M |
| Current liabilities | $18.05M | $318,284 | $313,858 | $395,756 | $302,926 |
| Short-term debt | $1.14M | — | — | — | — |
| Long-term debt | $5.47M | — | — | — | — |
| Total debt | $6.61M | — | — | — | — |
| Total liabilities | $23.66M | $318,284 | $313,858 | $395,756 | $302,926 |
| Shareholders' equity | -$11.75M | $827,219 | $3.99M | $5.17M | $4.79M |
| Net debt | $6.45M | — | — | — | — |
| Shares outstanding | 1.11M | 2.25M | 2.25M | 1.66M | 13.75M |
| Cash flow statement | |||||
| Operating cash flow | -$3.07M | -$3.16M | -$4.29M | -$4.61M | -$4.14M |
| Investing cash flow | -$3.17M | — | — | — | — |
| Financing cash flow | $10.31M | — | $3.14M | $5.14M | $3.90M |
| Stock-based compensation | $1.39M | $418,422 | $773,203 | $1.55M | $2.60M |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.